The authors highlighted that despite developments in the medical management of metastatic breast cancer, little is known about the quality of life (QoL) and experience of care for these women. QoL was assessed using the Functional Assessment of Cancer Therapy—Breast QoL measure. They concluded that despite improvements in treatment and survival of women with metastatic breast cancer, this group report high symptom burden and dissatisfaction with elements of their care, indicating that alternative models of service delivery should be explored.